Leukeran (Chlorambucil)

Chlorambucil exerts its antineoplastic effect by alkylating DNA strands, creating cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, preferentially eliminating rapidly dividing cancer cells while sparing most normal tissues.

The dosage of Leukeran is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the specific indication, patient weight, renal and hepatic function, and overall treatment plan. Patients should follow the prescribing information provided by their healthcare professional.

Leukeran is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided in pregnant women and used only when the potential benefit justifies the risk. Breastfeeding is not recommended because chlorambucil can be excreted in milk and may harm the infant.

To request Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Leukeran (chlorambucil) is a nitrogen mustard‑type alkylating agent with oral administration, whereas agents like cyclophosphamide are often given intravenously. Chlorambucil has a longer half‑life and is frequently used for chronic, indolent malignancies, while cyclophosphamide is preferred for more aggressive cancers. Both share similar mechanisms but differ in toxicity profiles and dosing schedules.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Leukeran is taken orally as a tablet with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary restrictions to minimize gastrointestinal upset.

The most serious risks include secondary malignancies such as acute leukemia, severe infections due to profound neutropenia, pulmonary fibrosis or interstitial lung disease, and significant hepatic or renal toxicity. Patients should be monitored regularly for signs of infection, respiratory symptoms, and organ function abnormalities.

Leukeran is contraindicated in patients with known hypersensitivity to chlorambucil or other alkylating agents, in pregnant women, and in individuals with severe bone‑marrow suppression, uncontrolled hepatic or renal impairment, or active infections that could be worsened by immunosuppression.